Major Histocompatibility Complex Class I antigen presentation machinery (MHC-I APM)

The Major Histocompatibility Complex Class I (MHC-I) antigen presentation machinery is a multi-component system essential for the adaptive immune system's ability to monitor intracellular health (Source: StatPearls, PMID: 31194374). It functions by degrading endogenous proteins via the proteasome, transporting the resulting peptides into the endoplasmic reticulum through the Transporter associated with Antigen Processing (TAP), and loading them onto MHC-I molecules with the help of the peptide-loading complex (Source: UniProt, P17918). These peptide-MHC-I complexes are then trafficked to the cell surface, where they are surveyed by CD8+ cytotoxic T lymphocytes (Source: NIH, National Cancer Institute). In the context of oncology, tumors frequently downregulate or lose components of this machinery—such as Beta-2 microglobulin (B2M) or TAP1—to evade immune surveillance and resist T-cell-based therapies (Source: PMID: 30612167). Therapeutic strategies often focus on upregulating these components using cytokines like Interferon-gamma or epigenetic modifiers to restore the visibility of cancer cells to the immune system (Source: PubMed, PMC6328530). Consequently, the integrity of this machinery serves as a critical determinant of the success of modern immunotherapies, including immune checkpoint inhibitors and CAR-T cell therapies (Source: Nature Communications, 2019).

Other names

MHC class I pathwayHLA class I antigen presentation pathwayAntigen processing and presentation pathwayMHC-I pathwayClass I antigen processing machinery

Induction of gene expression for MHC-I heavy chains, B2M, and processing components such as TAP and LMP to enhance the display of intracellular antigens to cytotoxic T lymphocytes (Source: PMID: 30612167).